Cenicriviroc is a new experimental once-daily oral tablet that may improve liver fibrosis in patients with NASH by targeting and blocking the immune and inflammatory pathways responsible for fibrosis. If licensed, cenicriviroc has the potential to establish itself as both a single-agent and as a cornerstone treatment for NASH.
Cenicriviroc for non-alcoholic steatohepatitis (NASH)
Interventions:
Cenicriviroc (TAK-652; Cenicriviroc Mesylate)
Indications:
Non-alcoholic steatohepatitis (NASH)
Therapeutic Areas:
Hepatology
Year:
2017